MarketPulse

enrollment violations

3 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Pomerantz Llp

Nektar Therapeutics Faces Class Action Over Failed Trial Data Disclosure

Pomerantz LLP filed securities fraud class action against Nektar Therapeutics, alleging false statements about clinical trial enrollment procedures led to trial failure and stock decline.
NKTRsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Portnoy Law Firm

Nektar Therapeutics Faces Class Action Over Failed Trial and Alleged Disclosure Failures

Nektar Therapeutics faces class action lawsuit over alleged failure to disclose enrollment protocol violations in failed Phase 2b REZOLVE-AA trial, triggering 8% stock decline.
NKTRclass action lawsuitstock decline
GlobeNewswire Inc.GlobeNewswire Inc.··Robbins Llp

Nektar Therapeutics Faces Securities Class Action Over Failed Trial Disclosure

Nektar Therapeutics faces securities class action over alleged misstatements about REZOLVE-AA trial, with stock falling 7.77% after trial failure announcement.
NKTRclass actionstock price decline